A phase 2 trial of the somatostatin analog pasireotide to prevent GI toxicity and acute GVHD in allogeneic hematopoietic stem cell transplant

BACKGROUND: Allogeneic hematopoietic stem cell transplantation (HCT) is an often curative intent treatment, however it is associated with significant gastrointestinal (GI) toxicity and treatment related mortality. Graft-versus-host disease is a significant contributor to transplant-related mortality...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramalingam, Sendhilnathan, Siamakpour-Reihani, Sharareh, Bohannan, Lauren, Ren, Yi, Sibley, Alexander, Sheng, Jeff, Ma, Li, Nixon, Andrew B., Lyu, Jing, Parker, Daniel C., Bain, James, Muehlbauer, Michael, Ilkayeva, Olga, Kraus, Virginia Byers, Huebner, Janet L., Spitzer, Thomas, Brown, Jami, Peled, Jonathan U., van den Brink, Marcel, Gomes, Antonio, Choi, Taewoong, Gasparetto, Cristina, Horwitz, Mitchell, Long, Gwynn, Lopez, Richard, Rizzieri, David, Sarantopoulos, Stefanie, Chao, Nelson, Sung, Anthony D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8232534/
https://www.ncbi.nlm.nih.gov/pubmed/34170918
http://dx.doi.org/10.1371/journal.pone.0252995

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8232534/
https://www.ncbi.nlm.nih.gov/pubmed/34170918
http://dx.doi.org/10.1371/journal.pone.0252995

Ejemplares similares